"Nelfinavir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.
| Descriptor ID |
D019888
|
| MeSH Number(s) |
D03.633.100.531.520
|
| Concept/Terms |
Nelfinavir Mesylate- Nelfinavir Mesylate
- Mesylate, Nelfinavir
- Nelfinavir Monomethane Sulfonate
- Monomethane Sulfonate, Nelfinavir
- Sulfonate, Nelfinavir Monomethane
|
Below are MeSH descriptors whose meaning is more general than "Nelfinavir".
Below are MeSH descriptors whose meaning is more specific than "Nelfinavir".
This graph shows the total number of publications written about "Nelfinavir" by people in this website by year, and whether "Nelfinavir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 1 | 2 |
| 2004 | 2 | 0 | 2 |
| 2017 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nelfinavir" by people in Profiles.
-
A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. Clin Pharmacol Ther. 2021 10; 110(4):1057-1065.
-
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PLoS One. 2017; 12(7):e0181357.
-
SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS. 2004 Jul 23; 18(11):1529-37.
-
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis. 2004 Jul 15; 190(2):280-4.
-
Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003 Dec 05; 17(18):2603-14.
-
Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003 Jan 01; 32(1):18-29.